Febutaz 20
Reading File
Searching the Web
Febutaz 20 febuxostat tablet uses dosage
Finding Sources
Reading File
Reading File
Here is a complete drug profile for Febutaz 20 (Febuxostat 20 mg):
Febutaz 20 - Febuxostat 20 mg
Febutaz 20 is an Indian brand of febuxostat, manufactured as a 20 mg tablet. This is a lower-than-standard starting dose used for initiating therapy or dose titration, particularly in patients with renal or hepatic concerns.
Drug Class
Xanthine oxidase (XO) inhibitor - urate-lowering therapy (ULT)
Mechanism of Action
Febuxostat potently and specifically inhibits xanthine oxidase, the enzyme responsible for converting hypoxanthine and xanthine into uric acid. Unlike allopurinol:
- It does not have a purine-like backbone - it has a distinct non-purine structure
- It is metabolized primarily by oxidation and glucuronidation in the liver, so renal elimination plays a minor role
- It does not affect pyrimidine metabolism and is not re-incorporated into nucleotides
(Rheumatology, 2-Volume Set, 2022, Elsevier)
Indications
- Chronic management of hyperuricemia in gout
- Second-line agent when allopurinol is not tolerated, contraindicated, or has failed
- Particularly useful in patients with renal impairment (CKD stages 1-3), where allopurinol dose adjustment is complex
- Not indicated for asymptomatic hyperuricemia
Dosage
| Situation | Dose |
|---|---|
| Standard starting dose | 40 mg once daily |
| Inadequate response after 2 weeks | Increase to 80 mg once daily |
| Severe renal impairment | Max 40 mg once daily |
| Europe/some countries | Up to 120 mg once daily approved |
Note on Febutaz 20 mg: The 20 mg dose is a sub-standard dose, typically used as a cautious starting dose in Indian clinical practice for renal impairment or as dose titration. The globally recommended starting dose is 40 mg.
Can be taken with or without food, and with antacids.
(Goodman & Gilman's Pharmacological Basis of Therapeutics)
Key Clinical Data
- 40 mg/day febuxostat achieves similar serum urate lowering as 300 mg/day allopurinol
- 80 mg/day achieves target serum uric acid (<6 mg/dL) in more patients than allopurinol 300 mg/day
- In stage 3 CKD, febuxostat 40-80 mg achieves target urate more frequently than dose-adjusted allopurinol
Adverse Effects
| Effect | Detail |
|---|---|
| Gout flares (early) | Common at initiation due to urate mobilization from tissue deposits |
| Liver function abnormalities | Monitor LFTs periodically |
| Nausea | Common |
| Rash | <2% incidence |
| Joint pain | Reported |
| Cardiovascular warning | BLACK BOX WARNING - higher rate of MI and stroke vs. allopurinol (CARES trial: ~20-30% higher risk for CV death). Use only when allopurinol is not appropriate. |
(Goodman & Gilman's; Firestein & Kelley's Textbook of Rheumatology)
Contraindications & Interactions
- Contraindicated with azathioprine or mercaptopurine (XO inhibition raises their plasma levels to toxic concentrations)
- Inhibits BCRP transporter - avoid rosuvastatin doses >20 mg/day concurrently
- Theophylline: minor pharmacokinetic interaction, not clinically significant at 80 mg/day
Gout Flare Prophylaxis at Initiation
When starting febuxostat, concurrent prophylactic treatment with colchicine or an NSAID is typically recommended for the first few months to prevent early flares triggered by urate mobilization.
Monitoring
- Serum uric acid at 2 weeks (target: <6 mg/dL, <5 mg/dL in tophaceous gout)
- Liver function tests periodically
- Cardiovascular status, especially in patients with pre-existing CV disease
Comparison with Allopurinol
| Feature | Febuxostat | Allopurinol |
|---|---|---|
| Structure | Non-purine | Purine analog |
| Metabolism | Hepatic (oxidation/glucuronidation) | Renal (as oxypurinol) |
| Renal dose adjustment | Not required (mild-moderate CKD) | Required in CKD |
| Pyrimidine metabolism | Not affected | Affected |
| CV safety | Lower (black box warning) | Preferred |
| Cost | Higher | Lower |
Bottom line: Febutaz 20 mg is a low-dose formulation of febuxostat used in India, typically as an initiation or titration dose. The standard effective dose is 40-80 mg daily. Given its black box cardiovascular warning, it is generally reserved for patients who cannot tolerate or have failed allopurinol.
This is a shared conversation. Sign in to Orris to start your own chat.